pathogen

(redirected from ESKAPE pathogens)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to ESKAPE pathogens: Klebsiella pneumoniae, Enterococcus faecium

path·o·gen

 (păth′ə-jən)
n.
An agent that causes disease, especially a virus, bacterium, or fungus.

pathogen

(ˈpæθəˌdʒɛn) or

pathogene

n
(Pathology) any agent that can cause disease

path•o•gen

(ˈpæθ ə dʒən, -ˌdʒɛn)

n.
any disease-producing agent, esp. a virus, bacterium, or other microorganism.
[1940–45]

path·o·gen

(păth′ə-jən)
An agent that causes infection or disease, especially a microorganism, such as a bacterium or protozoan, or a virus. See Note at germ.

pathogen

A disease-producing microorganism.

pathogen

1. A disease-causing organism.
2. A microorganism that causes disease.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.pathogen - any disease-producing agent (especially a virus or bacterium or other microorganism)
microorganism, micro-organism - any organism of microscopic size
infectious agent, infective agent - an agent capable of producing infection
Translations
patogeenitaudinaiheuttaja

pathogen

[ˈpæθəʊdʒen] Npatógeno m

pathogen

[ˈpæθədʒɛn] nagent m pathogène

pathogen

n (Med) → Krankheitserreger m

pathogen

[ˈpæθəˌdʒɛn] nagente m patogeno

path·o·gen

n. patógeno, agente capaz de producir una enfermedad.

pathogen

n patógeno, agente patógeno
References in periodicals archive ?
Session title and location: P507 - Antimicrobial Agents: Mechanisms of Action and Mechanisms of Resistance in Gram-negative ESKAPE Pathogens
ContraFect announced that the combating antibiotic resistant bacteria biopharmaceutical accelerator, or CARB-X, has awarded the company up to $6.94M in non-dilutive funding to accelerate the development of its newly discovered and proprietary class of amurin peptides as potential therapeutics to treat serious and potentially life-threatening infections, including those caused by antibiotic-resistant Gram-negative ESKAPE pathogens. The company intends to progress these compounds as quickly as possible through hit-to-lead and optimization towards clinical development as potential treatments for pulmonary exacerbations of cystic fibrosis and hospital-acquired bacterial pneumonia, or HABP, including ventilator associated bacterial pneumonia.
The firm's libraries offer coverage of ESKAPE pathogens.
Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010;31 Suppl 1:S7-10.
These new antibiotics' unique mechanism of action allows maximize penetration of bacterial cells leading to potent activity against drug-resistant ESKAPE pathogens.